OCATA THERAPEUTICS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OCATA THERAPEUTICS

OCAT 8.470

0.0%

Feb 11 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	11/27/2012 4:21:43 PM
	of 134

RT... Regeneron Pharms EYLEA injection approved for the treatment of Wet Age-Related Macular Degeneration in Europe Co announces that EYLEA injection has been approved by the European Commission for the treatment of patients with neovascular age-related macular degeneration. EYLEA was approved for the treatment of neovascular AMD in the United States in November 2011 and in Japan, Australia, Switzerland, and other countries this year. Bayer HealthCare (BAYRY) plans to launch EYLEA in these countries later in 2012 and into 2013. In the United States, EYLEA was also approved for the treatment of Macular Edema following Central Retinal Vein Occlusion in September 2012.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next